3 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
Follow Pharmasoft: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults Mexidol, Standard Therapy - Vascular Cognitive Impairment no Dementia | Phase 4 | Completed | Pharmasoft | 120 | 2025-09-14 | 2026-07-14 |
| MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG) Mexidol - Primary Open-Angle Glaucoma (POAG) | Phase 4 | Completed | Pharmasoft | 80 | 2023-09-15 | 2025-12-12 |
| MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure Mexidol - Ischemic Stroke, Acute | Phase 4 | Completed | Pharmasoft | 60 | 2023-04-17 | 2025-04-27 |
Brain Injuries, Traumatic (1) · Cognitive Dysfunction (1) · Glaucoma (1) · Glaucoma, Open-Angle (1) · Ischemic Stroke (1) · Mitochondrial Diseases (1) · Stroke (1)
emoxypine succinate (3) · ethylmethylhydroxypyridine succinate (2) · Standard of Care (1)
Russia (3)